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After acute coronary syndrome, diabetic patients
with peripheral vascular disease remain at high risk
of cardiovascular events despite secondary
prevention measures
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Summary
Background.— Peripheral vascular disease (PVD) is associated with a high risk of cardiovascular
events after an acute coronary syndrome (ACS). The impact of suboptimal risk-factor control
and drug prescription on morbidity and mortality rates in patients with PVD following an ACS
remains to be established.
Aims.— To assess whether a global atherosclerosis management programme and optimal sec-prevention;
Patient education;
Diabetes
ondary prevention could beneﬁt high-risk PVD patients after an ACS.
Methods.— A total of 851 ACS patients underwent an intensiﬁed intervention focusing on
evaluating risk factors and atherosclerosis lesions, and on optimizing treatment and education.
We compared its impact on long-term risk factors, medication observance and cardiovascular
Abbreviations: CAD, coronary artery disease; CI, conﬁdence interval; LDL, low-density lipoprotein; MACE, major adverse cardiac
events; MICE, minor adverse cardiac events; PVD, peripheral vascular disease; TIA, transient ischaemic attack.
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outcomes in patients with coronary artery disease (CAD) alone (n = 715, 84.0%) and with both
CAD and PVD (n = 136).
Results.— At a median follow-up of 18.6months, both groups reached recommended secondary
prevention goals and showed no signiﬁcant differences in rates of drug prescription. PVD was not
associated with minor cardiovascular events (hazard ratio [HR] 1.32, 95% conﬁdence interval
[CI] 0.57—3.02) but remained independently associated with major (HR 2.15, 95% CI 1.12—4.13)
and total (HR 1.76, 95% CI 1.05—2.93) cardiovascular events. Compared to patients with CAD
alone, this risk was signiﬁcantly higher in CAD patients with both PVD and diabetes (HR 2.87,
95% CI 1.52—5.43), but not in PVD patients without diabetes (HR 1.35, 95% CI 0.71—2.56) or
diabetic patients without PVD (HR 1.11, 95% CI 0.68—1.81).
Conclusion.— Despite optimization of risk-factor control and drug prescription after ACS,
patients with both PVD and diabetes carry a 2.9-fold higher risk of cardiovascular events at
18-month follow-up versus patients with CAD alone. This excess risk was not signiﬁcant in PVD
patients without diabetes or in diabetic patients without PVD.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé
Introduction.— La présence d’une artériopathie périphérique (AP) est associée à un haut risque
d’évènement cardiovasculaire (CV) après un syndrome coronarien aigu (SCA). La responsabilité
du contrôle insufﬁsant des facteurs de risque et de la prescription médicamenteuse sur cette
morbimortalité élevée n’a pas été établie chez ces patients.
Méthode.— Huit cent cinquante et un patients consécutifs ayant présenté un SCA ont bénéﬁcié
d’une intervention intensive visant à évaluer les facteurs de risque résiduels, la charge en
athérome, et à optimiser les traitements et l’éducation thérapeutique et diététique. Nous
avons comparé l’impact de ce programme à long terme sur l’équilibre des facteurs de risque, le
maintien du traitement et les événements cliniques dans deux groupes : groupe 1 avec atteinte
coronaire seule (n = 715 ; 84,0 %) ; groupe 2 avec coronaropathie et AP (n = 136 ; 16,0 %).
Résultats.— Au terme d’un suivi médian de 18,6mois, les objectifs de prévention secondaire ont
été atteints dans les deux groupes qui ne présentaient pas de différence en termes de prescrip-
tions médicamenteuses. La présence d’une AP n’est pas associée à un sur-risque d’évènements
CV mineurs (HR 1,32 ; 95 % CI 0,57—3,02) mais reste un facteur indépendant de survenue
d’évènement CV majeur (HR 2,15 ; 95 % CI 1,12—4,13) et d’évènement CV total (HR 1,76 ; 95 %
CI 1,05—2,93) (p < 0,05). Ce risque est signiﬁcativement plus élevé chez les patients porteurs
d’une AP et d’un diabète (HR 2,87 ; 95 % CI 1,52—5,43 ; p = 0,0012), mais pas chez ceux ayant
une AP sans diabète (HR 1,35 ; 95 % CI 0,71—2,56 ; p = 0,35), ni chez ceux ayant un diabète
sans AP (HR 1,11 ; 95 % CI 0,68—1,81 ; p = 0,68) en comparaison avec les patients avec atteinte
coronaire seule.
Conclusion.— Malgré l’optimisation du contrôle des facteurs de risque CV et des prescriptions
médicamenteuses, les patients diabétiques avec AP ont un risque d’événement CV à 18mois
d’un SCA 2,9 fois plus élevé que les patients avec coronaropathie seule, mais cet excès de risque
n’est pas signiﬁcatif en cas d’AP chez les non-diabétiques, ni chez les patients diabétiques sans
. Tous droits réservés.
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ackground
eripheral vascular disease (PVD) is associated with a
arked increased risk of cardiovascular events [1—3].
atients with known coronary artery disease (CAD) have a
oorer prognosis when they have coexisting PVD [4—8].
While secondary prevention guidelines for patients with
AD and other atherosclerotic vascular diseases are identi-
al in their recommendations [9—12], patients with PVD are
ess likely than those with CAD to be prescribed the rec-
mmended therapies [13—15]. Even in patients with known
AD, contemporary data show a lower rate of drug pres-
ription after myocardial infarction when PVD is present.
a
o
p
h
lhis could in part explain the higher mortality and mor-
idity observed in the PVD population [16,17]. The optimal
se of evidence-based therapies for secondary prevention is
xpected to improve modiﬁable major risk factors, and sub-
equently reduce cardiovascular morbidity and mortality.
owever, evidence of their clinical beneﬁt remains poorly
eﬁned in PVD subjects.
The aim of this study was to assess whether a global
therosclerosis management programme combined with
ptimal secondary prevention could beneﬁt high-risk PVD
atients after an acute coronary syndrome (ACS). We
ypothesized that an aggressive evidence-based drug and
ifestyle intervention programme implemented in patients
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ePrognosis of patients with PVD after an ACS
with an ACS would be equally beneﬁcial, ﬁrstly in improving
risk proﬁle, and secondly in reducing the higher morbidity
and mortality rates observed in ACS patients with versus
without coexisting PVD.
Patients and methods
Between January 2002 and June 2005, a cohort of consecu-
tive patients hospitalized for an established ACS in Bordeaux
Heart Hospital Intensive Care Unit, and in whom a coro-
nary angiogram during the acute phase was performed, was
enrolled at the Center of Exploration, Prevention and Treat-
ment of Atherosclerosis (CEPTA) three days after the ACS.
The CEPTA programme has been described elsewhere [18].
Brieﬂy, it comprised initiation of secondary prevention mea-
sures before hospital discharge, including prescription of
optimal treatment, and an extensive evaluation of cardio-
vascular risk factors, myocardial disease and atherosclerotic
burden at three months. Discharge therapy was adapted to
cardiac and vascular status and risk factors in accordance
with international guidelines [19,20]. At follow-up, a ques-
tionnaire was sent to each patient to determine lifestyle
habits, current treatments and cardiovascular or other out-
comes.
Acute-phase management
ACS was deﬁned and treated according to the American
College of Cardiology guidelines [20]. An early coronary
angiogram was performed in each patient, allowing precise
evaluation of coronary lesions and optimized acute-phase
management. The most suitable treatment was delivered
during the ﬁrst week, according to the guideline recommen-
dations.
Intervention at three months
Assessment of left ventricular ejection
fraction and residual myocardial ischaemia
An echocardiography was performed to assess global systolic
ventricular function and wall motion abnormalities, comple-
mented by an isotopic measure of ejection fraction. Residual
myocardial ischaemia was evaluated by thallium-201 per-
fusion single-photon emission computed tomography during
exercise.
Assessment of atherosclerosis burden
Atherosclerosis burden was evaluated by measuring coro-
nary, carotid and lower-limb atherosclerosis, as follows:
• coronary atherosclerosis: a reduction of ≥ 50% in the
diameter of one epicardial vessel on coronary angiogra-
phy was considered to be a signiﬁcant coronary stenosis,
in addition to the lesion responsible for the ACS;
• carotid atherosclerosis: carotid ultrasound duplex imag-
ing measured the intima medial thickness of the far wall
of the common carotid arteries [21] and the percentage
of internal carotid artery stenosis [22];
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lower-limb atherosclerosis: ankle brachial index (ABI)
measurement was performed with the patient in the
supine position after≥ 5min of rest [8].
isk factor management and medical
reatment
ach patient underwent evaluation of their reported
ifestyle in relation to smoking habits, diet and physical
ctivity. Family history of myocardial infarction was identi-
ed. Height and weight were measured and body mass index
kg/m2) was calculated. Blood pressure was monitored over
he course of 1 h with the patient in the supine position,
nd the mean measurement was used in the data analysis.
blood sample was drawn by vein puncture after a 12-
our fast to measure lipid concentrations (total cholesterol,
igh-density lipoprotein and low-density lipoprotein [LDL]
holesterol, triglycerides, lipoprotein[a]), glucose (fasting
lucose, HbA1c), creatinine clearance and inﬂammatory
arkers (high-sensitive C-reactive protein, ﬁbrinogen).
Diabetes mellitus was deﬁned as fasting gly-
aemia≥ 7mmol/L in two consecutive measures or when
ntidiabetic drugs had been prescribed previously. Hyper-
ension was deﬁned as systolic blood pressure≥ 140mmHg
nd/or diastolic blood pressure≥ 90mmHg. Dyslipidaemia
as deﬁned as LDL cholesterol > 3.35mmol/L.
Treatment at hospital discharge was consistently adapted
o cardiac and vascular status, to risk factors and to speciﬁc
oals to be attained, in accordance with international guide-
ines [19]. The aim of dietary intervention was a total daily
ntake of fat < 30% of the daily energy intake and an intake
f saturated fatty acids < 10% of the daily energy intake.
dietician provided patient-speciﬁc weight-management
uidance. On two occasions, educational classes lasting 2 h
ere provided that covered all aspects of coronary artery
isease risk, including lifestyle modiﬁcation, smoking ces-
ation, hypertension and lipid and diabetes management,
nd provided comprehensive risk-reduction counselling to
mprove observance to treatment. A smoking cessation spe-
ialist was involved for current smokers. Light-to-moderate
xercise lasting≥ 30min three times a week was recom-
ended.
eﬁnitions of PVD: organization of patient
roups
n order to evaluate the impact of the extent of atheroscle-
osis lesions on outcome after an ACS, patients were
ategorized into two groups according to the presence
deﬁned as an ABI < 0.9) or absence of PVD: CAD alone and
AD and PVD.
atient follow-up and deﬁnition of
ndpointsollow-up was carried out with a standardized question-
aire, previously validated in clinical trials [18,23], sent
o each patient and physician 18months after discharge
rom the CEPTA evaluation. Nurses in charge of patient
ducation telephoned the patients at their homes and/or
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heir physicians, whenever needed (i.e., when there was
n address and/or phone number change or for medical
etails). The questionnaire covered aspects of lifestyle
abits including former or current smoking and level of
hysical activity. Symptoms of reinfarction, stroke, PVD and
urgical treatment (revascularization by angioplasty, coro-
ary artery bypass grafting, carotid endarterectomy) after
ospital discharge were researched. The medical records of
he subjects who died, or who reported on the question-
aire that they had experienced symptoms or any clinical
utcome between baseline evaluation and follow-up, were
eviewed by one of the investigators, and patient practi-
ioners were contacted. The patient’s practitioner measured
lood pressure and weight. Current medication was noted.
At follow-up, treatments, risk-factor proﬁle and car-
iovascular events were evaluated. Events included total
vents (cardiovascular death, ACS, stroke or transient
schaemic attack [TIA], congestive heart failure, secondary
oronary revascularization or peripheral vascular surgery),
ajor adverse cardiovascular events (MACE; cardiovascular
eath, ACS, stroke or TIA) and minor adverse cardiovascular
vents (MICE; congestive heart failure, coronary or periph-
ral vascular revascularization).
tatistical analysis
aseline characteristics, ACS management, atherosclerotic
esions, treatment and risk factors at follow-up of patients
ithout PVD were compared with those presenting with
VD using the t test and the 2 test, as appropriate. A
ox proportional-hazards regression analysis in univariate or
ultivariable models was used for further analysis of inde-
endent variables predicting the occurrence of events at
ollow-up after adjustment for potentially confounding vari-
bles. Covariates that were tested in the model included
VD, non-modiﬁable risk factors (age, sex) and modiﬁable
isk factors (hypertension, smoking, dyslipidaemia and dia-
etes). With the aim of determining predictors of events,
atients who presented an event during follow-up were
F
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Table 1 Acute phase management, early complications of acu
function.
Variable
Revascularizationa within ﬁrst 36 h (%)
Medicalb treatment (%)
In-hospital complicationsc (%)
In-hospital heart failure (%)
Isotopic ejection fraction (%)
Ejection fraction≤ 40% (%)
Atherosclerosis burden
Mean number of coronary vessels with≥ 50% stenosise
Ankle brachial index > 1.4 (%)
Carotid stenosis≥ 50% (%)
Intima medial thickness > 0.7mm (%)
CAD: coronary artery disease; PVD: peripheral vascular disease.
a Angioplasty or coronary artery bypass graft.
b No reperfusion therapy delivered for the treatment of ACS.
c Recurrent acute coronary syndrome, ventricular tachycardia, supravM. Laﬁtte et al.
ompared to those who did not by use of the t test for contin-
ous variables and the 2 statistic for categorical variables.
aking these results into account, Cox proportional-hazards
egression was used to assess the risk of cardiovascular
vents in patients with CAD and PVD, with CAD and diabetes,
nd with CAD and both PVD and diabetes, with hazards ratios
iven in comparison with CAD alone as a reference group. A
value≤ 0.05 was considered to be statistically signiﬁcant.
he software for statistical analysis was STATA (StataCorp
P, College Station, Texas).
esults
rom January 2002 to June 2005, 851 consecutive men and
omen presenting with an ACS were hospitalized at CEPTA
or an optimized atherosclerosis secondary prevention pro-
ramme and were enrolled in the study. According to the
xtent of atherosclerosis, 715 patients (84.0%) presented
ith CAD alone and 136 patients (16.0%) with CAD and PVD.
cute phase management and evaluation
t three months
atients with CAD and PVD were more likely than those with
AD alone to receive medical treatment and they had a
reater atherosclerotic burden (Table 1).
Table 2 shows the demographic and baseline character-
stics of patients three months after the index event. In
omparison with CAD alone, patients with both CAD and PVD
ere older and had a higher prevalence of cardiovascular
isk factors despite treatment initiated after the ACS.ollow-up results
he median length of follow-up was 18.6months (interquar-
ile range 15.6—24.5). Twenty-six patients died and 29
ere lost to follow-up; data were therefore available in
te coronary syndromes, atherosclerosis burden and cardiac
CAD (n = 715) CAD +PVD (n = 136) p
87.7 75.6 < 0.001
12.3 24.4 < 0.001
20.3 21.7 0.80
3.0 3.8 0.80
55.3± 12 53.7± 11 0.52
10.5 14.1 0.39
1.45± 0.8 1.67± 0.8 < 0.01
7.1 —
5.7 19.3 < 0.0001
41.5 63.9 0.001
entricular arrhythmia, pericarditis, heart failure.
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Table 2 Baseline and demographic characteristics of patients three months after an ACS.
Variable CAD (n = 715) CAD +PVD (n = 136) p
Demographic
Mean age (years) 58.1± 12 63.8± 12 < 0.0001
Women (%) 17.0 20.8 0.31
Dyslipidaemia characteristics
Total cholesterol (mmol/L) 4.88± 1.0 5.09± 1.0 0.03
High-density lipoprotein cholesterol (mmol/L) 1.28± 0.3 1.28± 0.3 0.65
Low-density lipoprotein cholesterol (mmol/L) 2.87± 0.8 2.97± 0.9 0.14
Low-density lipoprotein > 3.35mmol/L (%) 28.9 35.6 0.15
Triglycerides (mmol/L) 1.80± 1.8 2.22± 2.5 0.06
Diabetes characteristics
Fasting glucose (mmol/L) 5.98± 1.6 6.61± 2.6 0.014
HbA1c (%) 5.96± 0.9 6.34± 1.1 < 0.001
Presence of diabetes (%) 24.0 38.3 < 0.001
Diabetes duration (years) 10.0± 8 11.0± 8 0.34
Obesity characteristics
Body mass index (kg/m2) 27.4± 4 27.9± 5 0.78
Waist circumference (cm) 98.7± 12 101.7± 11 0.004
Metabolic syndrome ATP III (%) 22.6 35.8 0.002
Hypertension characteristics
Systolic blood pressure (mmHg) 118± 16 123± 21 0.001
Diastolic blood pressure (mmHg) 67± 10 66± 11 0.11
Systolic blood pressure > 140mmHg (%) 10.7 20.3 0.003
Creatinine concentration (mmol/L) 94.1± 43 99.1± 37 0.24
Smoking status (%) 0.026
Former smoker 55.2 62.2
Current smoker 17.3 21.8
Never smoked 27.5 16.0
Family history of cardiovascular disease (%) 32.7 25.2 0.11
Inﬂammatory markers
High sensitivity C-reactive protein (mg/L) 3.4± 4 4.2± 4 < 0.001
High sensitivity C-reactive protein > 5mg/L (%) 18.5 30.3 0.006
Fibrinogen (g/L) 3.7± 0.8 4.0± 0.9 0.003
Physical activity < 0.001
Low (%) 57.3 75.4
Recommended (%) 42.7 24.6
CS: a
t
p
w
d
t
i
p
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iCAD: coronary artery disease; PVD: peripheral vascular disease; A
796 (96.6%) eligible patients. In this single-centre study,
which included an educational programme and was led by
trained nurses who were also in charge of the follow-up,
very few patients and/or physicians could not be reached
at 18months. Treatment at follow-up showed a high level
of prescription of guideline-recommended secondary pre-
vention drugs in both groups, with no statistical difference
between the two, except for a higher number of antihyper-
tensive drugs given to patients with CAD and PVD (Table 3).
Despite a higher prevalence of modiﬁable cardiovascular
risk factors at three-month evaluation in the PVD versus non-
PVD group (Table 2), no signiﬁcant differences were found at
follow-up between the two groups, except for HbA1c, which
was higher in patients with CAD and PVD (Table 3). Moreover,
lipid concentrations and blood pressure measures met the
a
w
A
s
icute coronary syndrome.
arget goals recommended by guidelines in a very high pro-
ortion of subjects in both groups (Table 3). Diabetes control
as equivalent in the two groups. There was no signiﬁcant
ifference between groups in the rate of current smokers or
he level of physical activity (Table 3).
The incidences of MACE, MICE and total events dur-
ng follow-up were 13.3%, 8.3% and 21.6%, respectively, in
atients with CAD and PVD and 5.8%, 5.0% and 10.8% in
atients with CAD alone. In these post-ACS patients receiv-
ng optimal secondary prevention treatment, multivariable
nalysis showed that PVD remained signiﬁcantly associated
ith cardiovascular events during follow-up (Tables 4 and 5).
nalysis of variables inﬂuencing the cardiovascular progno-
is of this cohort also found a signiﬁcant and independent
nﬂuence of diabetes (Table 5).
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Table 3 Cardiovascular risk factors and treatment at follow-up.
Variable CAD n = 676 (84.9%) CAD +PVD n = 120 (15.1%) p
Treatment at follow-up
Beta-blocker and/or calcium antagonist 85.9 84.6 0.81
Angiotensin-converting enzyme/angiotensin II
receptor blocker
59.6 69.3 0.17
Mean number of hypertensive drugs 1.9± 0.8 2.2± 1.0 0.009
Antiplatelet therapy or warfarin 94.4 100 0.73
Lipid-lowering drug 89.8 83.9 0.69
Combination of beta-blocker and/or calcium
antagonist/antiplatelet or
warfarin/lipid-lowering drugs
75.4 72.5 0.77
Dyslipidaemia characteristics
HDL cholesterol (mmol/L) 1.27± 0.3 1.25± 0.3 0.43
LDL cholesterol (mmol/L) 2.72± 0.7 2.66± 0.8 0.65
LDL cholesterol > 3.35mmol/L (%) 16.4 19.2 0.71
Triglycerides (mmol/L) 1.54± 1.1 1.96± 2.2 0.061
Diabetes characteristics
Fasting glucose (mmol/L) 5.89± 1.8 6.53± 2.7 0.054
HbA1c (%) 5.9± 0.9 6.2± 1.0 0.045
HbA1c among diabetic patients (%) 7.0 7.2 0.59
HbA1c > 7% (%) 47.2 50.0 0.78
Body mass index (kg/m2) 27.4± 4 28.2± 4 0.71
Hypertension characteristics
Systolic blood pressure (mmHg) 129± 12 131± 9 0.18
Diastolic blood pressure (mmHg) 74± 8 74± 7 0.86
Systolic blood pressure > 140mmHg (%) 4.3 7.5 0.11
Current smoker (%) 20.4 22.4 0.70
Fibrinogen concentration (g/L) 3.56± 0.9 3.44± 0.7 0.47
Physical activity 0.46
Low (%) 40.5 34.2
Recommended (%) 59.6 65.8
i
w
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pCAD: coronary artery disease; PVD: peripheral vascular disease.The risk proﬁle of patients presenting an event dur-
ng follow-up was compared with that of patients who
ere event-free, and showed signiﬁcant differences in fast-
ng glycaemia concentration (6.64mmol/L vs 5.99mmol/L,
< 0.001), HbA1c (6.42% vs 5.96%, p > 0.0001), presence of
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Table 4 Unadjusted and adjusted hazard ratios (95% conﬁde
MICE during follow-up after an acute coronary syndrome in pa
CAD alone).
Unadjusted Adjuste
Total events 2.12 (1.34—3.37) p = 0.0014 2.00 (1.
MACE 2.49 (1.37—4.54) p = 0.0027 2.43 (1.
MICE 1.70 (0.82—3.56) p = 0.15 1.53 (0.
MACE: minor adverse cardiovascular events (cardiovascular death, ac
MICE: minor adverse cardiovascular events (congestive heart failure, c
artery disease.
a Hypercholesterolemia, hypertension, smoking and diabetes.iabetes (36% vs 24%, p < 0.01), poorer control of diabetes
HbA1c 7.3% vs 6.8%, p < 0.05) and presence of PVD (26.3%
s 13.5%, p < 0.0001).
Cox proportional-hazards regression found that, in com-
arison to CAD alone, in patients with PVD, diabetes was
nce intervals) for occurrence of total events, MACE and
tients with peripheral vascular disease (reference group:
d for age and sex Further adjusted for major
cardiovascular risk factorsa
26—3.20) p = 0.038 1.76 (1.05—2.93) p = 0.031
33—4.45) p = 0.0039 2.15 (1.12—4.13) p = 0.021
73—3.22) p = 0.26 1.32 (0.57—3.02) p = 0.53
ute coronary syndrome, stroke or transient ischaemic attack);
oronary or peripheral vascular revascularization); CAD: coronary
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Table 5 Proportional hazard regression analysis for total events during follow-up after an acute coronary syndrome
(reference group: CAD alone).
Univariate hazard
ratio (95% CI)
p Multivariable hazard
ratio (95% CI)
p
Age (per 1-year increase) 1.02 (1.01—1.04) 0.006 1.01 (1.00—1.03) 0.12
Male sex 1.30 (0.77—2.21) 0.32 1.52 (0.82—2.83) 0.18
Hypercholesterolaemia 1.02 (0.70—1.49) 0.92 1.10 (0.72—1.70) 0.65
Hypertension 1.41 (0.83—2.40) 0.20 1.14 (0.63—2.07) 0.66
Current smoking 0.89 (0.54—1.48) 0.65 0.98 (0.54—1.80) 0.95
Diabetes 1.69 (1.16—2.48) 0.0068 1.70 (1.09—2.64) 0.019
PVD (ABI < 0.9) 2.96 (1.34—3.37) 0.0014 1.76 (1.05—2.93) 0.031
ABI > 1.4 1.10 (0.51—2.37) 0.81 — —
ABI: ankle brachial index; CI: conﬁdence interval; PVD; peripheral vascular disease; CAD: coronary artery disease.
Table 6 Occurrence of total events during follow-up after an acute coronary syndrome in patients with CAD and PVD,
CAD and diabetes, CAD and both PVD and diabetes (reference group: CAD alone).
Vascular disease beds Hazard ratio (95% conﬁdence interval) p
CAD(+), PVD(+), diabetes(−) 1.35 (0.71—2.56) 0.35
CAD(+), PVD(−), diabetes(+) 1.11 (0.68—1.81) 0.68
CAD(+), PVD(+), diabetes(+) 2.87 (1.52—5.43) 0.0012
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iCAD: coronary artery disease; PVD: peripheral vascular disease.
associated with a 2.9-fold excess risk of total cardiovas-
cular events whereas no signiﬁcant risk excess was shown
in PVD patients without diabetes. Moreover, diabetes was
not signiﬁcantly associated with the occurrence of cardio-
vascular events in the absence of PVD (Table 6). Thus, the
excess morbidity—mortality rate in this cohort of post-ACS
patients with improved risk proﬁle could be attributed to
the comorbid association of PVD and diabetes, whereas PVD
or diabetes separately were not signiﬁcant predictors of a
poorer outcome.
Discussion
These observational data demonstrate that a specialized
intervention programme focused on patient education and
optimization of treatment can improve both the risk-factor
proﬁle of patients and use of evidence-based therapies over
the long-term after an ACS, with similar ﬁndings in patients
with and without PVD. Second, PVD remains a risk marker of
cardiovascular events despite optimal secondary prevention
following an ACS but is not associated with poorer prognosis
in patients without diabetes. Third, the association of dia-
betes and PVD appears to be the main factor contributing to
a more complicated course, whereas diabetes in patients
without PVD was not associated with higher cardiovascu-
lar morbidity and mortality in patients receiving optimal
treatment after an ACS.
Coronary patients have a poorer cardiovascular progno-
sis when lower limb peripheral artery disease is present
[4—8]. Their worse outcome may be attributed in part to
less-aggressive treatment during the early management of
v
s
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sCS, greater prevalence of atherosclerosis risk factors and
uboptimal use of recommended therapies [15,16]. Patients
ith atherothrombotic disease in multiple vascular beds are
nown to carry a higher residual risk proﬁle than patients
ith CAD alone [17]. Thus, we sought to treat risk factors
ore aggressively in an effort to reach established sec-
ndary prevention goals. The risk proﬁle of patients with
VD in our study, three months after an ACS, is consistent
ith previously reported data on secondary prevention fail-
re [5,15], showing a high prevalence of residual risk factors
hree months after an ACS despite secondary prevention
easures. The CEPTA programme of global atherosclerosis
anagement demonstrated its efﬁciency in improving both
he rates of use of recommended drug therapies and the
ong-term cardiovascular risk proﬁle of PVD patients after
n ACS. As a result, the two groups of patients met estab-
ished targets for lipids, glucose and blood pressure a median
f 18.6months after our intervention. To the best of our
nowledge, this is the ﬁrst demonstration that very high-
isk patients with ACS and PVD can beneﬁt from such a
rogramme in terms of risk-proﬁle improvement.
Previous studies have shown consistent data on poorer
utcomes after an ACS when PVD was present, even in
symptomatic subjects [7,8,24]. Our present data suggest
hat even though optimal long-term medical care reduced
ardiovascular risks following an ACS in patients with PVD,
t failed to demonstrate any capacity to lower the cardio-
ascular event rate to that of patients without PVD. The
econdary prevention goals may, however, have been insuf-
cient to achieve this aim. Our results are in accordance
ith a recent report from the REduction of Atherothombo-
is for Continued Health (REACH) Registry in patients with
1p
o
r
A
s
p
[
d
b
s
w
a
h
f
p
u
b
i
g
a
h
i
a
o
r
D
e
E
c
m
f
t
v
t
r
t
s
t
w
i
r
a
a
t
m
a
p
a
r
t
o
C
T
o
t
a
f
p
w
a
p
C
N
R
[04
eripheral artery disease, which showed that good control
f cardiovascular risk was not associated signiﬁcantly with a
eduction in the risk of total cardiovascular events [25].
The prevalence of diabetes mellitus in patients with an
CS was high in the present study, and diabetes has been
hown to remain an independent marker of unfavourable
rognosis despite improvement in the management of ACS
26]. Our study showed that diabetic subjects without PVD
id not have a poorer prognosis than patients without dia-
etes. In other respects, PVD in non-diabetic patients had no
igniﬁcant implications for outcome. The factor associated
ith poorer prognosis in patients receiving optimized man-
gement was the association of diabetes and PVD, a very
igh-risk group in which this type of secondary prevention
ailed.
The reasons for failure of secondary prevention in
atients with both PVD and diabetes in this study remain
nclear. Patients with PVD were older and at higher risk,
ut analysis of variables that affect prognosis showed little
nﬂuence of any except diabetes. The secondary prevention
oals of this cohort corresponded to recommended values
t the time of the study. Since then, LDL cholesterol goals
ave been lowered to 1.81 mmol/L in very high-risk patients,
ncluding those with PVD [10]. Our study may not evaluate
potential greater beneﬁt of current recommended sec-
ndary prevention with lower LDL-cholesterol values. Most
ecently, both the Action to Control Cardiovascular Risk in
iabetes (ACCORD) and Action in Diabetes and Vascular Dis-
ase: Preterax and Diamicron Modiﬁed Release Controlled
valuation (ADVANCE) studies failed to demonstrate the efﬁ-
acy of intensive glycaemic control on the occurrence of
acrovascular events in patients with diabetes [27,28]. In
act, while the microvascular prognosis is improved with
reatment of hyperglycaemia, macrovascular prognosis is
ery poorly affected by glycaemic control in diabetes. In
his study, the HbA1c levels of diabetic patients reached the
ecommended 7% level, which remains the most appropriate
arget for prevention of macrovascular events. Recent data
hed doubt over the protective effect of low-dose aspirin in
he prevention of cardiovascular events in diabetic patients
ith PVD [29]. In this study, a high proportion of patients,
ncluding those with diabetes, received low-dose aspirin as
ecommended for secondary prevention in the long-term
fter an ACS [29]. In the Steno-2 study, an intervention
imed at several modiﬁable risk factors was able to reduce
he risk of cardiovascular events in type 2 diabetics with
icroalbuminuria [30,31]. Our results conﬁrm the efﬁcacy of
n intensiﬁed multifactorial treatment approach in diabetic
atients without PVD, even after an ACS, and are encour-
ging in non-diabetic subjects with PVD. However, future
esearch should focus on deﬁning new targets for risk fac-
ors or new treatment strategies that might improve the
utcome of coronary patients with both PVD and diabetes.
onclusionhese results, with notable clinical implications in the ﬁeld
f secondary prevention, suggest better and earlier iden-
iﬁcation of a very high-risk coronary population with PVD
nd diabetes who are in need of secondary prevention rein-
orcement. Optimization of risk-factor control and drug
[M. Laﬁtte et al.
rescription resulted in a better prognosis for PVD patients
ithout diabetes and for diabetic patients without PVD after
n ACS, but was insufﬁcient to control cardiovascular risk in
atients with diabetes and PVD.
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